Trial Profile

A pivotal study assessing MGTA-456

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 17 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Spanlecortemlocel (Primary)
Indications Transplant rejection
Focus Registrational; Therapeutic Use
Sponsors Dianthus Therapeutics; Magenta Therapeutics

Most Recent Events

20 Feb 2020 According to a Magenta Therapeutics media release, the company intends to continue dialogue with the FDA under the RMAT designation on design of a registration-enabling study, and to have discussions with the European Medicines Agency for development in Europe as well.
06 Sep 2019 New trial record
04 Sep 2019 According to a Magenta Therapeutics media release, this study is expected to start in 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com